



January 11, 2017

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of final USFDA approval for Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25%, to market a generic equivalent of Taro Pharmaceuticals North America, Inc's Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc's (collectively Taro) Topicort® Cream, 0.25%.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

  
For **R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



## **Lupin Receives FDA Approval for Generic Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%**

**Mumbai, January 11, 2017:** Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% from the United States Food and Drug Administration (FDA) to market a generic equivalent of Taro Pharmaceuticals North America, Inc's Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc's (collectively Taro) Topicort® Cream, 0.25%.

Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% are the AB rated generic equivalent of Taro's Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%. Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort® LP emollient Cream had US sales of USD 33 million (IMS MAT September 2016) while Topicort® Cream had US sales of USD 17 million (IMS MAT September 2016).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5<sup>th</sup> and the 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (December 31<sup>st</sup>, 2016, Bloomberg) and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3<sup>rd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31<sup>st</sup> March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

**For further information or queries please contact –**

Shamsher Gorawara

Head – Corporate Communications

Ph: +91-98 20 338 555

Email: [shamshergorawara@lupin.com](mailto:shamshergorawara@lupin.com)

## Press Release



**LUPIN**

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

or

Arvind Bothra

Head – Investor Relations and M&A

Ph: +91-70 45 656 895

Email: arvindbothra@lupin.com

*\*Safe Harbor Statement*

*Topicort® is the registered trademark of Taro Pharmaceuticals USA, Inc. and or its affiliates.*